-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $357

Benzinga·07/30/2026 18:59:05
Listen to the news
Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $510 to $357.